aspirin has been researched along with Eosinophilia, Pulmonary in 9 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Excerpt | Relevance | Reference |
---|---|---|
"Although administration of cromolyn sodium is one of the most useful drugs for the treatment of aspirin-intolerant asthma (AIA), both its pharmacologic mechanism of action and association with the pathogenesis remain obscure." | 9.09 | Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. ( Akahori, K; Amayasu, H; Hasegawa, H; Ishizaki, Y; Nakabayashi, M; Nakagawa, H; Shoji, T; Yoshida, S, 2001) |
"Theophylline is commonly used to treat severe asthma and chronic obstructive pulmonary disease (COPD) characterized by non-eosinophilic inflammation." | 7.76 | Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma. ( Choi, DS; Choi, JP; Gho, YS; Jeon, SG; Kim, YK; Kim, YS; Moon, HG; Yoon, CM, 2010) |
"These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity." | 5.30 | Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019) |
"Although administration of cromolyn sodium is one of the most useful drugs for the treatment of aspirin-intolerant asthma (AIA), both its pharmacologic mechanism of action and association with the pathogenesis remain obscure." | 5.09 | Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. ( Akahori, K; Amayasu, H; Hasegawa, H; Ishizaki, Y; Nakabayashi, M; Nakagawa, H; Shoji, T; Yoshida, S, 2001) |
"Theophylline is commonly used to treat severe asthma and chronic obstructive pulmonary disease (COPD) characterized by non-eosinophilic inflammation." | 3.76 | Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma. ( Choi, DS; Choi, JP; Gho, YS; Jeon, SG; Kim, YK; Kim, YS; Moon, HG; Yoon, CM, 2010) |
"Acute eosinophilic pneumonia was diagnosed." | 1.30 | [Acute eosinophilic pneumonia associated with aspirin]. ( Kurihara, Y; Matsuda, K; Sekiguchi, S; Uchida, K, 1997) |
"We believe that this patient's pulmonary disease was caused by Bufferin." | 1.30 | [Bufferin-induced lung injury manifesting as acute eosinophilic pneumonia]. ( Aoki, S; Iwase, A; Kawabata, Y; Matsuoka, R; Nagayama, T; Nakaya, Y; Sakamoto, K; Shimizu, K; Shiota, S, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 3 (33.33) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors | Studies |
---|---|
Nelson, RK | 1 |
Bush, A | 1 |
Stokes, J | 1 |
Nair, P | 1 |
Akuthota, P | 1 |
Weinstein, SF | 1 |
Katial, RK | 1 |
Bardin, P | 1 |
Korn, S | 1 |
McDonald, M | 1 |
Garin, M | 1 |
Bateman, ED | 1 |
Hoyte, FCL | 1 |
Germinaro, M | 1 |
Moon, HG | 1 |
Kim, YS | 1 |
Choi, JP | 1 |
Choi, DS | 1 |
Yoon, CM | 1 |
Jeon, SG | 1 |
Gho, YS | 1 |
Kim, YK | 1 |
Uchida, K | 1 |
Sekiguchi, S | 1 |
Matsuda, K | 1 |
Kurihara, Y | 1 |
Shimizu, K | 1 |
Shiota, S | 1 |
Nakaya, Y | 1 |
Sakamoto, K | 1 |
Iwase, A | 1 |
Aoki, S | 1 |
Matsuoka, R | 1 |
Nagayama, T | 1 |
Kawabata, Y | 1 |
Amayasu, H | 1 |
Nakabayashi, M | 1 |
Akahori, K | 1 |
Ishizaki, Y | 1 |
Shoji, T | 1 |
Nakagawa, H | 1 |
Hasegawa, H | 1 |
Yoshida, S | 1 |
Marvisi, M | 1 |
Fornasari, G | 1 |
Medici, TC | 1 |
Sandhaus, Y | 1 |
Weisbrod, M | 1 |
Schreiber, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039] | Phase 3 | 489 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323] | Phase 3 | 464 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.676 |
Reslizumab 3.0 mg/kg | -0.941 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.695 |
Reslizumab 3.0 mg/kg | 0.933 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.109 |
Reslizumab 3.0 mg/kg | 0.167 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
Intervention | liters (Least Squares Mean) |
---|---|
Placebo | 0.110 |
Reslizumab 3.0 mg/kg | 0.248 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | puffs/day (Least Squares Mean) |
---|---|
Placebo | -0.36 |
Reslizumab 3.0 mg/kg | -0.64 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
Intervention | CAEs in 52 weeks (Mean) |
---|---|
Placebo | 1.804 |
Reslizumab 3.0 mg/kg | 0.904 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)
Intervention | weeks (Median) |
---|---|
Placebo | 34.9 |
Reslizumab 3.0 mg/kg | NA |
The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52
Intervention | participants (Number) |
---|---|
Reslizumab 3.0 mg/kg | 8 |
"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
---|---|---|
Over first 16 weeks | Over 52 weeks | |
Placebo | -0.118 | -0.127 |
Reslizumab 3.0 mg/kg | -0.584 | -0.582 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
Intervention | CAEs in 52 weeks (Mean) | |
---|---|---|
Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
Placebo | 1.604 | 0.207 |
Reslizumab 3.0 mg/kg | 0.722 | 0.137 |
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each
Intervention | participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
At least 1 AE | Mild severity AE | Moderate severity AE | Severe AE | Treatment-related AE | Treatment-related mild AE | Treatment-related moderate AE | Treatment-related severe AE | AE causing patient discontinuation | Serious AE | Deaths | |
Placebo | 206 | 41 | 133 | 32 | 36 | 23 | 13 | 0 | 8 | 34 | 1 |
Reslizumab 3.0 mg/kg | 197 | 68 | 107 | 22 | 36 | 24 | 9 | 3 | 4 | 24 | 0 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
Intervention | participants (Number) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blood urea nitrogen | Uric acid | Aspartate aminotransferase | Alanine aminotransferase | Gamma-glutamyl transpeptidase | Bilirubin | White blood cells - low | White blood cells - high | Hemoglobin | Hematocrit | Neutrophils | Eosinophils | Platelets - low | Platelets - high | Urinalysis - Blood (hemoglobin) | Urinalysis - Ketones | Urinalysis - Glucose | Urinalysis - Protein | |
Placebo | 9 | 9 | 1 | 3 | 12 | 2 | 6 | 5 | 7 | 9 | 8 | 135 | 1 | 2 | 32 | 4 | 11 | 32 |
Reslizumab 3.0 mg/kg | 8 | 6 | 1 | 5 | 12 | 1 | 6 | 3 | 4 | 6 | 6 | 3 | 2 | 0 | 21 | 5 | 14 | 34 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
Intervention | participants (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sitting pulse - high 12-17 yr | Sitting pulse - low >=18 yr | Sitting pulse - high >=18 yr | Sitting systolic blood pressure - low >=18 yr | Sitting systolic blood pressure - high >=18 yr | Sitting diastolic blood pressure - low 12-17 yr | Sitting diastolic blood pressure - low >=18 yr | Sitting diastolic blood pressure - high >=18 yr | Respiratory rate >=18 yr | Body temperature - low 12-17 yr | Body temperature - low >=18 yr | Body temperature - high >=18 yr | |
Placebo | 1 | 1 | 5 | 2 | 7 | 1 | 0 | 10 | 3 | 1 | 54 | 0 |
Reslizumab 3.0 mg/kg | 1 | 0 | 7 | 5 | 7 | 0 | 1 | 5 | 2 | 1 | 49 | 1 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.660 |
Reslizumab 3.0 mg/kg | -0.857 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.777 |
Reslizumab 3.0 mg/kg | 0.987 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.080 |
Reslizumab 3.0 mg/kg | 0.115 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
Intervention | liters (Least Squares Mean) |
---|---|
Placebo | 0.122 |
Reslizumab 3.0 mg/kg | 0.223 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
Intervention | liters (Least Squares Mean) |
---|---|
Placebo | 0.094 |
Reslizumab 3.0 mg/kg | 0.187 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
Intervention | SABA puffs per day (Least Squares Mean) |
---|---|
Placebo | -0.44 |
Reslizumab 3.0 mg/kg | -0.50 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
Intervention | CAEs in 52 weeks (Mean) |
---|---|
Placebo | 2.115 |
Reslizumab 3.0 mg/kg | 0.859 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)
Intervention | weeks (Median) |
---|---|
Placebo | NA |
Reslizumab 3.0 mg/kg | NA |
"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
---|---|---|
Over first 16 weeks | Over 52 weeks | |
Placebo | -0.076 | -0.076 |
Reslizumab 3.0 mg/kg | -0.555 | -0.565 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
Intervention | CAEs in 52 weeks (Mean) | |
---|---|---|
Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
Placebo | 1.660 | 0.047 |
Reslizumab 3.0 mg/kg | 0.646 | 0.033 |
Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
Baseline | Week 16 | Week 32 | Week 48 | Week 52 | >=1 positive test result | |
Reslizumab 3.0 mg/kg | 10 | 10 | 10 | 10 | 10 | 15 |
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
Intervention | participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Mild TEAE | Moderate TEAE | Severe TEAE | Treatment-related AE | Mild treatment-related AE | Moderate treatment-related AE | Severe treatment-related AE | TEAE causing patient discontinuation | Deaths | Serious AEs | |
Placebo | 201 | 36 | 140 | 25 | 27 | 14 | 13 | 0 | 9 | 0 | 23 |
Reslizumab 3.0 mg/kg | 177 | 67 | 98 | 12 | 34 | 22 | 11 | 1 | 8 | 0 | 18 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52
Intervention | participants (Number) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blood urea nitrogen | Creatinine | Urate | AST | ALT | GGT | Bilirubin | Leukocytes (low) | Leukocytes (high) | Hemoglobin | Hematocrit | Eosinophils/leukocytes | Platelets | Neutrophils | Urine blood (hemoglobin) | Urine ketones | Urine glucose | Urine protein | |
Placebo | 5 | 0 | 5 | 3 | 7 | 11 | 3 | 3 | 0 | 5 | 10 | 168 | 1 | 14 | 28 | 6 | 9 | 28 |
Reslizumab 3.0 mg/kg | 4 | 1 | 2 | 2 | 3 | 9 | 3 | 10 | 1 | 6 | 8 | 10 | 1 | 9 | 12 | 1 | 7 | 28 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52
Intervention | participants (Number) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
>=1 postbaseline vital sign abnormality | Sitting pulse (high) | Sitting systolic blood pressure (low) | Sitting systolic blood pressure (high) | Sitting diastolic blood pressure (low) | Sitting diastolic blood pressure (high) | Respiratory rate (low) | Respiratory rate (high) | Body temperature (low) | Body temperature (high) | |
Placebo | 58 | 6 | 2 | 0 | 4 | 3 | 0 | 4 | 50 | 1 |
Reslizumab 3.0 mg/kg | 49 | 6 | 1 | 1 | 3 | 4 | 1 | 5 | 39 | 0 |
1 review available for aspirin and Eosinophilia, Pulmonary
Article | Year |
---|---|
[Is the lung a target organ in inflammatory bowel disease?].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bronchial Diseases | 2001 |
2 trials available for aspirin and Eosinophilia, Pulmonary
Article | Year |
---|---|
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma.
Topics: Adult; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Blood Protei | 2001 |
6 other studies available for aspirin and Eosinophilia, Pulmonary
Article | Year |
---|---|
Eosinophilic Asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Child; Humans; Hypersensitivit | 2020 |
Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; | 2010 |
[Acute eosinophilic pneumonia associated with aspirin].
Topics: Acute Disease; Adult; Aspirin; Bronchoalveolar Lavage Fluid; Humans; Interleukin-5; Lymphocyte Activ | 1997 |
[Bufferin-induced lung injury manifesting as acute eosinophilic pneumonia].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Lung Diseases; Pulmonary Eo | 1997 |
[Drug-induced lung diseases].
Topics: Aspirin; Asthma; Bronchitis; Busulfan; Contraceptives, Oral, Hormonal; Dose-Response Relationship, D | 1979 |
[Loeffler syndrome in a child treated with aspirin].
Topics: Aspirin; Child, Preschool; Female; Humans; Pulmonary Eosinophilia | 1990 |